Stock SPAG SPAGO NANOMEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Spago Nanomedical AB

Equities

SPAG

SE0004899474

Delayed Nasdaq Stockholm
Other stock markets
 11:06:16 2024-04-29 am EDT 		5-day change 1st Jan Change
0.36 SEK 0.00% Intraday chart for Spago Nanomedical AB +18.42% +10.09%
Apr. 24 Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad CI
Apr. 16 Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SPAGO NANOMEDICAL AB Stock Spago Nanomedical AB
+10.09% 7.4M -
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.55% 10.81B
A-
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+47.97% 3.36B
D+
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-32.75% 2.22B
C
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-14.15% 2.16B -
B-
VERACYTE, INC. Stock Veracyte, Inc.
-26.06% 1.55B
C+
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+19.85% 1.04B
B-
SEEGENE, INC. Stock Seegene, Inc.
-2.62% 746M
C+
CAREDX, INC Stock CareDx, Inc
-31.67% 425M
C-
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-43.88% 405M
C-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. SPAG Stock
  4. Ratings Spago Nanomedical AB